PTPRC and acute myeloid leukemia: According to WHO, cytomorphology suggested the diagnosis of an AML with maturation (blasts 24.5%; segmented granulocyte 35.5%; monocytes 1.5%) and the immunophenotype corroborated the diagnosis of an AML (CD133(+)/CD34-/CD117+/CD13-/CD45(+)).